Development and Validation of a Method for Profiling Post-Translational Modification Activities Using Protein Microarrays by del Rincón, Sonia V. et al.
Development and Validation of a Method for Profiling
Post-Translational Modification Activities Using Protein
Microarrays
Sonia V. del Rinco ´n
1., Jeff Rogers
2., Martin Widschwendter
3, Dahui Sun
1, Hans B. Sieburg
1,
Charles Spruck
1*
1Signal Transduction Program, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America, 2Life Technologies Corporation, Carlsbad,
California, United States of America, 3Department of Gynaecological Oncology, University College London, London, United Kingdom
Abstract
Background: Post-translational modifications (PTMs) impact on the stability, cellular location, and function of a protein
thereby achieving a greater functional diversity of the proteome. To fully appreciate how PTMs modulate signaling
networks, proteome-wide studies are necessary. However, the evaluation of PTMs on a proteome-wide scale has proven to
be technically difficult. To facilitate these analyses we have developed a protein microarray-based assay that is capable of
profiling PTM activities in complex biological mixtures such as whole-cell extracts and pathological specimens.
Methodology/Principal Findings: In our assay, protein microarrays serve as a substrate platform for in vitro enzymatic
reactions in which a recombinant ligase, or extracts prepared from whole cells or a pathological specimen is overlaid. The
reactions include labeled modifiers (e.g., ubiquitin, SUMO1, or NEDD8), ATP regenerating system, and other required
components (depending on the assay) that support the conjugation of the modifier. In this report, we apply this
methodology to profile three molecularly complex PTMs (ubiquitylation, SUMOylation, and NEDDylation) using purified
ligase enzymes and extracts prepared from cultured cell lines and pathological specimens. We further validate this approach
by confirming the in vivo modification of several novel PTM substrates identified by our assay.
Conclusions/Significance: This methodology offers several advantages over currently used PTM detection methods
including ease of use, rapidity, scale, and sample source diversity. Furthermore, by allowing for the intrinsic enzymatic
activities of cell populations or pathological states to be directly compared, this methodology could have widespread
applications for the study of PTMs in human diseases and has the potential to be directly applied to most, if not all, basic
PTM research.
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Introduction
Post-translational modifications (PTMs) are essential for the
proper function of many proteins and dysregulation of these
processes is known to play a causative role in several human
diseases (reviewed in [1]). Modifications ranging from the simple
conjugation of a phosphate group to the complex addition of
ubiquitin can drastically alter the function of a protein. For
example, the conjugation of ubiquitin to a substrate can modulate
its activity, target it for degradation, alter its cellular location, or
determine its interaction with other proteins [2]. Despite the
importance of these modifications in maintaining cellular
homeostasis and contribution to human diseases, identifying
which proteins are modified by PTMs in mammalian cells on a
proteome-wide scale has proven technically difficult. Moreover,
methodologies for global proteomic analyses remain in their
infancy due in large part to challenges encountered with
developing proteomic platforms aimed at providing insight into
basic biological processes [3,4].
To overcome these technical limitations, we explored the
possibility of using protein microarrays as a platform for profiling
PTM activities. To date, the analysis of PTMs using protein
microarrays has been somewhat limited to the phospho-proteome,
profiling substrates of purified yeast enzymes, and characterizing
substrates of the anaphase-promoting complex (APC) ubiquitin
ligase [5,6,7,8]. Phosphorylation is a ‘simple’ PTM compared to
the complex enzymatic cascades required for many other
modifications such as the conjugation of ubiquitin and ubiquitin-like
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mediated by multi-step enzymatic reactions involving an activating
(E1), conjugating (E2), and ligase (E3) enzyme that function
consecutively to selectively transfer the PTM to substrates [1]. In
this report, we describe a protein microarray-based methodology
that is capable of profiling the ubiquitin and Ubl conjugation
activities of recombinant ligases, cellular fractions, whole-cell
extracts, and archival pathological specimens. We further apply
this methodology to 1) identify novel substrates of the SCF
Skp2
ubiquitin ligase, 2) profile for substrates of ubiquitylation,
NEDDylation, and SUMOylation activities in whole-cell extracts,
and 3) identify distinct changes in ubiquitin activity that associate
with human tumor progression.
Results
Optimization of a protein microarray-based method to
profile PTM activities
A schematic of our methodology is shown in Figure 1A.
Biochemical reactions are performed ‘on-chip’ by overlaying the
protein microarrays with a purified conjugating enzyme or extract
prepared from a biological specimen (e.g. cell line or pathological
specimen) and all required co-factors. The protein microarrays are
spotted with .8,000 different human recombinant proteins in
duplicate which serve as substrates for PTM conjugation. The
substrates are subsequently ‘tagged’ by conjugation of a labeled-
modifier (e.g. biotin) present in the reaction mixture. Following a
stringent wash toremove non-covalentsubstrate-modifierinteractions,
the PTM-conjugated substrates are then detected using ‘binders’ (e.g.
antibodies or streptavidin) labeled with fluorescent dyes and the
protein microarrays analyzed using a fluorescence slide scanner.
We first tried various configurations of ubiquitylation reactions
using cellular fractions (S-100) and rabbit reticulocyte lysate to
determine the optimal assay conditions. We evaluated different
slide surface chemistries, reaction buffers, assay conditions, and
detection methods. PATH slides (glass slides coated with
nitrocellulose) proved to be superior to epoxy or hydragel-coated
slides in reducing background (data not shown). The addition of
0.1% Tween-20 to both the reaction and wash buffers also
significantly limited background and did not adversely affect PTM
conjugation activity. Furthermore, the addition of inhibitors of de-
conjugating enzymes (e.g. ubiquitin-aldehyde) to the reactions was
found to increase PTM conjugation activity (data not shown).
Moreover, washing the protein microarrays with 1 M NaCl
+0.1% Tween-20 in PBS appeared to be sufficient for removing
the non-covalent binding of modifiers to substrates since washes
with 8 M urea, which is known to reduce non-covalent ubiquitin
binding, was found to give an identical conjugation profile (data
not shown). Although the use of protein microarrays to detect
substrates of ubiquitylation has been previously reported [7,8], we
evaluated the reproducibility of our optimized ‘on-chip’ ubiqui-
tylation reactions by statistically analyzing the results of three
independent ubiquitylation reactions using whole-cell HeLa cell
extract. Figure 1B shows an enlarged view of the same sub-array
region from each of the three protein microarray replicates,
wherein those spots producing fluorescent signals over background
were found to be present on all three sub-arrays. Statistical analysis
of the pair-wise scatter plots, plotting the signal intensity of each
protein for each biological replicate, revealed a high degree of
reproducibility between experiments (p,2.2 E-16; Fig. 1B).
Identifying substrates of purified SCF
Skp2 ubiquitin ligase
As proof of principle, we first sought to determine whether our
assay system could be used to faithfully identify substrates of a
purified E3 ubiquitin ligase. For these experiments, we utilized the
ubiquitin ligase SCF
Skp2 which has a well-defined role in human
tumorigenesis [9]. SCF
Skp2 is known to ubiquitylate several
different substrates including the cyclin-dependent kinase (Cdk)
inhibitor p27
Kip1 [10,11]. This reaction is molecularly complex
and requires 1) substrate phosphorylation, 2) association of the
substrate with cyclin A-Cdk2 complexes, and 3) the co-factor
protein Cks1. We performed ‘on-chip’ ubiquitylation reactions
that included recombinant human SCF
Skp2 isolated from Sf9
insect cells, purified E1 and E2 enzymes, ATP regeneration
system, ubiquitin, and biotin-labeled ubiquitin. The results of these
experiments showed that p27
Kip1 could be efficiently ubiquitylated
on the protein microarray by SCF
Skp2, and ubiquitin conjugation
activity was only present when all the required components were
added to the mixture, recapitulating the reaction conditions in vivo
(Fig. 1C). In addition to p27
Kip1, we identified several novel
substrates of SCF
Skp2 (Fig. 1C; see also Substrate validation
section).
Ubiquitylation reactions using cellular extracts
We next sought to determine whether this methodology could
be used to accurately profile the PTM activity of complex
biological mixtures, such as cellular extracts or pathological
specimens. Using a 2-fold change as a cutoff over negative
controls that lacked cellular extract, ubiquitylation reactions
performed with rabbit reticulocyte lysate and S-100 fraction of
HeLa cells revealed robust conjugation activities with 239 and
119 substrates identified, respectively (Table 1). Sixty-six
substrates were found to be common to both the rabbit
reticulocyte lysate and HeLa S-100 fraction (Table 2). Of these
substrates, several were previously shown to either bind ubiquitin
(e.g. LIVIN [12], RNF4 [13], ZNF364 [14]), contain ubiquitin
binding domains (e.g. CUED1C [15], RAD23A [16]), or were
known substrates of ubiquitylation activity (e.g. FLT1 [17], JAK2
[18], INSR [19]), lending strong support that this methodology
faithfully detects true substrates of ubiquitin conjugation activity.
We next profiled whole-cell extracts prepared from various
cultured cell lines of both human and mouse origin and found
these extracts efficiently ubiquitylated many (.120) different
substrates on the protein microarrays (Table 1; data not shown).
Approximately half of these substrates were found to be
consistently ubiquitylated by all the cellular extracts analyzed.
Collectively, these results demonstrate that this methodology
could be used to profile biologically relevant PTM activity in
complex biological specimens of various species origins.
Profiling changes in ubiquitylation activity associated
with human disease
A clinically relevant application of this methodology is
comparative profiling, wherein disease-associated changes in
PTM activity are compared to the normal state. To this end,
we applied this methodology to identify changes in ubiquityla-
tion activity that occurs during the progression of human
tumors to more advanced and life-threatening disease. Remark-
ably, we found that human breast tumor specimens that had
been kept frozen at 280uCf o r.10 years contained robust
ubiquitin conjugation activity (Table 1) comparable to that
observed for cellular fractions or whole-cell extracts prepared
from cultured cells. We next pooled extracts prepared from 5
low-grade and 5 high-grade breast tumors and performed ‘on-
chip’ ubiquitylation reactions with these extracts. Using a 1.6-
fold change as a cutoff over negative control reactions that
lacked tumor lysate, we identified several differentially ubiqui-
tylated substrates between the low-grade and high-grade
PTM Profiles on Protein Arrays
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in Figure 2 (fold changes are listed in Table S1). Interestingly,
the majority of the differentially ubiquitylated substrates were
found to have defined roles in several processes implicated in
tumor progression. One of the proteins showing increased
ubiquitylation in high-grade tumors was RAD23A [20,21].
RAD23 is implicated in DNA repair and is known to interact
with the E3 ligase E6AP, suggesting that its degradation by
ubiquitylation may contribute to tumor progression through
impairment of the DNA repair process. Moreover, TRIM52, a
protein that possesses intrinsic E3 ubiquitin ligase activity,
demonstrated increased ubiquitylation in high-grade tumors
suggesting that it may also be targeted for degradation by
ubiquitylation. In support of this, we found that TRIM52 is
indeed a target of the ubiquitin proteasome pathway (see
Substrate validation section).
Protein microarray-based profiling of Ubl modifications
SUMO1 and NEDD8
We next determined whether this methodology could be easily
adapted to other complex PTMs, such as SUMO1 (small
ubiquitin-like modifier 1) and NEDD8 (neural precursor cell
expressed and developmentally down-regulated 8). SUMO1 and
NEDD8 are conjugated to substrates in multi-step enzymatic
reactions similar to but distinct from ubiquitylation [22]. Reaction
conditions used in our assay were similar to those used for the
conjugation to ubiquitin (described above) except for the
substitution of the relevant reaction buffer, E1 enzyme, aldehyde
derivative, and biotin-labeled modifier. The results of these
experiments showed that HeLa cell extracts efficiently conjugated
SUMO1 and NEDD8 to many substrates on the protein
microarrays (Table 2). Of the putative SUMOylated substrates
identified, HIPK3 [23] and RNF4 [13] were previously shown to
Figure 1. PTM profiling on protein microarrays. (A) Schematic of protein microarray-based profiling of PTM activities. Protein microarrays which
display .8,000 recombinant human proteins spotted onto nitrocellulose-coated glass slides (in duplicate) provide a platform for assaying PTM
activity. Reactions are performed ‘on-chip’ using purified enzymes or extracts prepared from cells or a pathological specimen, ATP regenerating
system, modifier, and labeled-modifier (e.g. biotin-ubiquitin). PTM conjugation is then detected by incubating the slide with fluorescent-labeled
‘binders’ (e.g. streptavidin or antibodies) and activity quantified using a fluorescence slide reader. (B) Platform reproducibility. Shown are the results of
three protein microarrays ubiquitylated in separate experiments and enlarged region of the protein microarray is shown on the left. Also shown are
three pair-wise scatter plots that plot the signal intensity of each protein for the three biological replicates on the right. Statistical analysis of the data
is shown below. (C) Profiling substrates of the SCF
Skp2 ubiquitin ligase. Purified recombinant SCF
Skp2 complexes were applied to protein microarrays
in the presence of required co-factors (cyclin A-Cdk2 and Cks1). Insets show ubiquitylation of SCF
Skp2 substrate p27
Kip1 (red circle) and novel
substrates (blue circles). SCF core (ligase complex minus the Skp2 substrate recognition component) was used as control.
doi:10.1371/journal.pone.0011332.g001
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BC066929
12 CCDC55
1 FGFR3
2 LOC370014
1235 OR1Q1
1 RPL41
1 TSPAN17
12345
XM_375359
1 CCDC97
1 FGFR4
1 LOC440295
1 PAK1
4 RPS6KA1
2 TSPO
4
ABI1
1 CDC2
1 FGR
123 LOC51491
1 PAK3
1 RPS6KA4
145 TTK
14
ABL1
12 CDIPT
1 FLT1
14 LOC51765
45 PBK
1 RPS6KA5
145 TYRO3
14
ACBD6
12 CDK2/cyclinA
1 FLT3
1234 LOC55319
1 PDAP1
1 RPS6KB1
4 UBADC1
12345
ACVR1B
14 CDK9/cyclinT1
1 FLT4
14 LOC645591
4 PDCL
13 SCGB1C1
4 UBE2C
1
AHCYL1
2 CETN3
12 FRK
14 LOC83786
1 PDGFRalpha
1234 SCYE1
1 UBE2E2
15
ADRBK2
14 CHEK1
1 G3BP1
1 LOC84714
4 PELI1
1 SDCCAG3
1 UBE2H
25
AFF4
1 CHERP
4 GABRA3
1 LYN
123 PFDN5
45 SEPT1
1 UBE2O
124
AIM2
4 CHKA
4 GADD45G
12 MAGEB1
1 PIM1
125 SEPT5
1 UBE2S
125
AKT1
2 CHUK
1 GBA
4 MAP2
1 PIM2
145 SERPINA3
1 UBE3A
1235
ANKHD1
1 CLK3
4 GMNN
1 MAP2K2
1 PKN2
14 SGK
45 UBQLN2
2
ANKRD13A
1235 CNOT7
12 GNGT1
4 MAP2K3
145 PLK1
14 SGK3
4 UBXD1
13
ANKRD13D
12345 COPE
2 GRK4
145 MAP2K6
1 PLK3
14 SGPL1
1 UBXD8
1
ANKS4B
1 COPZ1
15 GRK6
14 MAP3K2
14 POMZP3
1 SH3BP5
1 VRK3
1
APOBEC4
1 CSAG1
1 GSDMDC1
12 MAP3K9
1 PRKCalpha
145 SIP1
4 WDFY1
4
ARL6IP4
1 CSF1R
123 GSK3B
14 MAP4K5
145 PRKCgamma
1 SLAIN2
3 WDR1
1
ASCC2
1 CSNK1D
14 GYG2
1 MAPK11
12 PRKCH
1 SLC6A13
1 WEE1
1
ASMTL
4 CSNK1E
1 HCK
12 MAPKAPK3
1 PRKCI
1 SMCR7
15 WIBG
2
ATF6
1 CSNK1G1
14 HGS
2 MAPKAPK5
12 PRKG2
14 SPATS2
1 YES1
123
ATP6V1G1
1 CSNK1G3
4 HOMER2
13 MARK2
1 PRKX
14 SPDEF
1 YY1
2
ATXN3
12345 CSNK2A1
1 HPCAL1
4 MATK
1 PRRG1
1235 SRMS
4 ZAP70
1
AURKB
1 CSNK2A2
14 HPGD
1 MERTK
14 PSMD4
12345 SRPK1
1 ZMYM5
123
BIN1
4 CUEDC1
12345 IFI44L
4 MET
1 PSRC1
1 SRPK2
1 ZNF313
1
BIRC7
124 CXorf48
2 IGF1R
123 MINK1
4 PTK2
1 SRPK3
1 ZNF364
12345
BLK
1 DAPK1
4 IKBKB
1 MPG
1 PTPN5
1 STIP1
1 ZNF434
4
BMX
1 DAPK2
1 ING5
1 MSRB3
4 RAB20
1 STK17A
14
BRAF
4 DHX32
1 INSR
14 MST1R
14 RABEP2
25 STK22D
1
BTK
14 DNAJB2
2 INSRR
145 MYL5
14 RAD23A
12345 STK25
1
C10orf97
123 DNAJC8
14 IRAK4
13 MYLK2
14 RAF1
4 STK3
145
C11orf52
1 DYRK3
14 IRF3
1 NAP1L2
1 RASGRP3
12 STK4
14
C11orf53
1 EIF5
1 IRS1
2 NBPF1
4 RASL11B
2 STRAP
1
C1orf165
1 EPHA1
12345 ITK
1 NDUFB6
4 RBCK1
1 SULF1
45
C1orf91
1 EPHA2
4 JAK2
145 NECAP1
1 RBM34
1 TAOK2
145
C20orf11
1 EPHA5
14 JAK3
14 NECAP2
1 RET
14 TAOK3
145
C2orf13
45 EPHA8
14 KDR
1234 NEK1
14 RHBDD1
2 TARBP2
1
C9orf78
1 EPHB3
4 KIAA1900
1 NEK2
1 RIOK3
12 TBK1
1
CACNB1
1 EPHB4
13 KIF2C
1 NEK4
1 RNF34
1345 TCP11
45
CALCOCO1
2 ERBB2
125 KIF3B
1 NEK6
1 RNF111
12345 TCP11L1
15
CAMK1
123 ERBB4
4 KIT
1 NEK9
145 RNF126
235 TEC
1
CAMK1D
1 FAM126B
2 LCK
1 NFKBIB
1 RNF128
2 TEK
14
CAMK2N1
1 FAM112B
1 LMNA
1 NGLY1
2 RNF130
2 TMEM139
2
CAMK2N2
12 FAM50A
1 LOC10572
2 NMT1
1 RNF185
1235 TNIK
1
CAMKIIalpha
1 FES
1 LOC112860
4 NR4A1
1 RNF4
1245 TNIP2
125
CAMKIIdelta
1 FER
4 LOC115460
1 NTRK1
1 ROR1
1 TOM1
125
CASQ2
1 FGF21
2 LOC120376
1 NTRK2
1 ROR2
45 TOM1L2
12345
CAT
1 FGFR1
12 LOC121457
4 NTRK3
1 ROS1
1 TRIM44
1
CCDC12
1 FGFR2
1 LOC284440
4 NUAK1
1 RPAIN
12 TRIM52
12345
1Rabbit reticulocyte lysates,
2Mouse embryonic fibroblasts,
3Human foreskin fibroblasts,
4HeLa cell S-100 fractions,
5Breast tumor specimens.
doi:10.1371/journal.pone.0011332.t001
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contained consensus SUMO1 targeting sequences (yKxE/D) [24].
Although only a few substrates of NEDDylation have been
reported in the literature [25,26,27], our screen did detect
LGALS3, which was previously shown to be NEDDylated using
an alternative proteomic approach [27]. Of note, we failed to
detect NEDDylation of the well-known NEDD8 target cullin
protein family with our assay (cullins 1, 3, 4a, and 4b are displayed
on the protein microarrays but the level of conjugation activities
did not meet our 2-fold cutoff criteria). This lack of activity could
be due to a number of factors. Although it is readily accepted that
cullins are NEDDylated on the Lys in the conserved sequence
IVRIMKMR [28], the accessory factors required for promoting
cullin NEDDylation may be molecularly complex and is still an
area of active investigation. In vitro evidence shows that the RING
finger protein Rbx1 is required for cullin NEDDylation
[29,30,31], while in vivo NEDDylation is enhanced by DCN1
[32]. Moreover, the ability to detect cullin protein NEDDylated
may be influenced by de-NEDDylase activities (e.g. COP9
Signalosome) [33]. Therefore, it is plausible that the activity of
Rbx1 or DCN1 present in our reactions was limiting or de-
NEDDylase activity was dominant in our assay. Alternatively,
these proteins may not be appropriately folded or pre-modified in
insect cells (used for recombinant protein expression) and cannot
be appropriately recognized by the NEDDylation machinery using
our reaction conditions.
Substrate validation experiments
To determine the accuracy of our assay system in detecting true
PTM conjugation activities, we first randomly selected c-Src, a
SCF
Skp2 substrate identified using our assay but not reported in
the literature, and determined if it was indeed a substrate of
SCF
Skp2 in vivo. c-Src is a non-receptor tyrosine kinase that plays
an important role in regulating cell proliferation and its
augmented expression promotes tumor cell invasion and metas-
tasis [34]. To validate c-Src as a novel SCF
Skp2 substrate, we
Table 2. Ubiquitin, NEDD8, and SUMO1 conjugated proteins identified on protein microarrays.
UBIQUITYLATION NEDDYLATION SUMOYLATION
UPS-associated Ubiquitin Substrates NEDD8 Substrates SUMO1 Substrates
ACVR1B* MST1R* ADRBK2 MYLK2 ANKHD1 LSM3 ADRBK1
ATXN3
F PDGFRalpha*
F ANKRD13D
F NEK1 ANKRD13D MAP3K10 AKT2
BTK* PLK1* CSNK1D NEK9 ANKRD17 MAP3K11 CDK5
CAT* PLK3* CSNK1G1 PIM2 ANKRD39 MAP3K9 CENPB
CUEDC1
F PRKCalpha* CSNK2A2 PKN2 ANKS4B MATK COPE
FLT1* PRKCgamma* DYRK3 PRKX BTK MCC FES
FLT3* PSMD4
F EPHA1 ROS1 CCDC69 MINK1 FGFR3
GSK3beta* RAD23A
F EPHA5 RPS6KA4 CENPB MST1R FGR
INSR* RET* FLT4 RPS6KA5 CETN3 NAP1L1 FYN
ITK RNF4 FRK STK3 CHEK1 NFKBIB HIPK3
JAK2* RNF111
F GRK4 STK4 CSNK2A1 OTUD6B HK1
JAK3* TTK* GRK6 STK17A CUEDC1 PAIP2 ING3
LIVIN UBADC1
F INSRR TAOK2 CXorf48 PAK1 JAK3
MAP3K2* UBE2O KIAA1900 TAOK3 DIXDC1 PAK3 LCK
MAP4K5* ZNF364
F MAP2K3 TEK EIF2B2 PBK LENG4
MCAK TRIM52 EPHA1 PDCL MAPKAPK5
MERTK TSPAN17 EPHB4 PEX19 MERTK
MYL5 TYRO3 FAIM PIM1 PAK3
FGR PRKCalpha PBK
GCC1 PRKCepsilon RBCK1
GOPC PSCD1 RIPK2
GSDMDC1 RAD23A RNF4
LCK RGS20 RPS6KA3
LGALS3 RPS6KB1 STK3
LMNA TOM1L2 VPS29
LOC126382 TRIM44 ZMYM5
LOC57596 UBOX5
Substrates shown for ubiquitin are common to both rabbit reticulocyte lysate and HeLa S-100 fractions.
Underlined, E3-associated;
*known substrate of ubiquitylation;
Bold, high homology to proteins known to be ubiquitylated;
F Superscript, substrates also common to human fibroblasts;
Italics, SUMO1 substrates containing SUMO consensus sequences (yKxE/D). UPS, ubiquitin proteasome system.
doi:10.1371/journal.pone.0011332.t002
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2/2 knockout MEFs with retroviruses that
express Skp2 and found this induced the down-regulation of c-
Src protein levels, consistent with its enforced degradation
(Fig. 3A). Moreover, immunoprecipitation of Skp2 from these cell
extracts revealed that endogenous c-Src associates with Skp2 in vivo
(Fig. 3B). Furthermore, ectopic expression of Skp2 in HEK293T
cells was found to stimulate c-Src ubiquitylation in vivo (Fig. 3C).
Collectively, these results are consistent with SCF
Skp2 regulating
the degradation of c-Src through ubiquitin-dependent proteolysis.
To further validate the accuracy of our methodology, we
randomly selected 10 substrates which were shown to be
ubiquitylated on the protein microarrays (by both rabbit
reticulocyte lysate and HeLa S-100 fraction) but whose modifica-
tion was not reported in the literature and attempted to verify
whether they were substrates of ubiquitylation in vivo. HEK293T
cells were co-transfected with plasmids that express HA-tagged
ubiquitin and the Myc- or GST-tagged substrates activin A
receptor-type IB (ACVR1B), beta-adrenergic receptor kinase 2
(ADRBK2), IL2-inducible T-cell kinase (ITK), protein kinase C-
gamma (PRKCgamma), ephrin type-A receptor 1 (EPHA1),
serine/threonine protein kinase PIM2, 90 kDa ribosomal protein
S6 kinase 5 (RPS6KA5), kinesin family member 2C (KIF2C),
ephrin type-A receptor 5 (EPHA5), or tripartite motif-containing
protein 52 (TRIM52) (Fig. S1). To determine whether these
substrates were covalently conjugated to ubiquitin in vivo,w e
subjected the HEK293T extracts to denaturing immunoprecipi-
tation, which included lysis of cells in buffer containing 1% SDS
and boiling the samples prior to immunoprecipitation [35]. Of the
8 substrates that were expressed and immunoprecipitated at
detectable levels all were found to be ubiquitylated in vivo (Fig. 4A;
data not shown). Bayesian statistical testing [36,37] of these results
verified that substrates that were ubiquitylated on the protein
microarrays had a high-probability of being true substrates of
ubiquitylation in vivo (the null hypothesis was tested H0: p=0.5
against the probability P*=0.63 derived from our validation data
and rejected with evidence ev=0.89). To confirm that the
observed ubiquitylation in vivo was not due to substrate
overexpression, we immunoprecipitated endogenous YY1 protein,
a putative substrate of ubiquitylation identified by our assay and
regulator of the MDM2 ubiquitin ligase that controls the
ubiquitin-dependent proteolysis of p53 [38], from HEK293T cell
extracts using denaturing conditions and analyzed its ubiquityla-
tion status by Western blot analysis. These experiments clearly
showed that endogenous YY1 was indeed ubiquitylated in vivo
(Fig. 4B).
We next tested the accuracy of our assay in profiling SUMO1
and NEDD8 conjugation activities using similar experimental
strategies. Immunoprecipitation of endogenous insulin-like growth
factor 1 receptor (IGF-1R), a receptor tyrosine kinase that
mediates IGF1 signaling [38], from HEK293T cell extracts using
Figure 2. Comparison of ubiquitylation changes in low and
high grade tumor samples by protein microarray analysis.
Column 4 lists the protein names sorted according to a directional
measure of fold-change in ubiquitylation status. Specifically, if the
median measurement for low grade tumors exceeded the median value
for high grade tumors we assigned a negative ratio of low/high.
Otherwise, a positive ratio was assigned. The directional change is
reflected in the heat map (Column 1), which shows the color
distribution across a red (smallest-negative) to green (highest-positive)
color spectrum. In the middle columns, the change of white to red
signifies that high fluorescence values in reactions containing low grade
tumor extract correspond to low fluorescence values in reactions
containing high grade tumor lysate, that is, the protein is more
ubiquitylated in low grade tumors compared to high grade tumors.
doi:10.1371/journal.pone.0011332.g002
PTM Profiles on Protein Arrays
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to SUMO1 in vivo (Fig. 5A). Furthermore, p21
Cip1-activated kinase
3 (Pak3), which is associated with non-syndromic mental
retardation in humans [39], and Musk, a receptor tyrosine kinase
that plays a role in neuromuscular junction organization [40],
were found to be covalently conjugated to NEDD8 in vivo (Fig. 5B).
Discussion
The results of our analyses demonstrate that our protein
microarray-based methodology can reliably and accurately profile
PTM conjugation activities in simple (e.g. purified PTM ligases) and
complex (e.g. whole-cell extracts) biological samples. The assay
system is highly reproducible, sensitive (can be performed with as
little as 2 mg of whole-cell extract), rapid (analysis can be completed
in a single day), and can be easily adapted to profile a variety of
different PTM conjugation activities. In this study, we used our
assay to 1) identify novel substrates of the SCF
Skp2 ubiquitin ligase,
2) profile ubiquitin, SUMO1, and NEDD8 conjugation activities of
whole-cell extracts, and 3) define changes in ubiquitylation activity
that associate with human breast tumor progression. As further
validation of this methodology, during the preparation of this
manuscript another group used a similar approach to identify novel
substrates of the APC ubiquitin ligase [8].
Figure 3. Validation of c-Src as a novel SCF
SKP2 substrate. (A) SKP2
2/2 MEFs were transduced with control (pBABEpuro) or Flag-Skp2-
expressing retroviruses and Western blot analysis was used to assess the expression level of known SCF
Skp2 substrate p27
Kip1 and putative substrate
c-Src. (B) Endogenous c-Src associates with Skp2 in vivo. Anti-Flag antibodies were used to immunoprecipitate Flag-Skp2 from extracts prepared from
SKP2
2/2 MEFs transduced with control (lanes 1 and 3) or Skp2-expressing retroviruses (lanes 2 and 4). Association of c-Src with Skp2 was determined
by Western blot analysis. The same blot was then re-probed with anti-Skp2 antibodies to verify immunoprecipitation. (C) Skp2 promotes c-Src
ubiquitylation in vivo. HEK293T cells were co-transfected with plasmids that express GST-c-Src, HA-Ubiquitin, with or without Flag-Skp2. Extracts from
cells were denatured, c-Src immunoprecipitated using anti-GST antibodies, and ubiquitylation detected by Western blotting with anti-HA antibodies.
doi:10.1371/journal.pone.0011332.g003
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proteome-wide scale include two-hybrid and high-copy suppressor
screens in yeast and mass spectrometry [27,41,42,43]. However,
these techniques have several limitations. For example, PTM
analysis by proteomic mass spectrometry can be hindered by 1)
low substrate abundance, a characteristic of many ubiquitylated
proteins, and/or a sub-stoichiometric level of PTM, 2) the labile
nature of many PTMs, making their preservation through
biochemical purification, separation, fragmentation, and analysis
problematic, especially if native conditions are required leaving
substrates vulnerable to de-conjugating enzymes, 3) the adverse
effects of certain PTMs on proteases, ionization, and detection
efficiency, and 4) multi-site or multi-species modifications, which
could make data interpretation problematic.
Our methodology overcomes many of these limitations and
provides several advantages over these currently employed
techniques. Since our assay relies on the intrinsic PTM
conjugation activity of a specimen it is less sensitive to substrate
concentrations and sub-stoichiometric modifications can be easily
detected. The reactions can also be performed with crude extracts
eliminating elaborate purification protocols that could promote
de-conjugation of the PTMs. Furthermore, we have successfully
multiplexed our assay system to simultaneously profile the
conjugation activities of several different PTMs simultaneously
on a single protein microarray using differentially labeled
fluorescent antibodies for PTM detection (data not shown).
However, there are some potential limitations with our assay
system. First, the protein microarrays used in this study display
,8,000 human proteins, representing only ,1/3 of the proteome.
Secondly, since the protein microarrays are produced with
recombinant human proteins expressed in Sf9 insect cells a
proportion of these substrates could be misfolded, possibly
precluding their modification or promoting their artificial
modification. Thirdly, our methodology may underestimate the
number of proteins post-translationally modified if the substrates
are printed on the microarrays in a manner that masks a specific
sequence that must be recognized by the PTM conjugating
enzyme, such as the ubiquitin ligase APC/C
CDC20 which uses a
destruction box motif (termed D box) for recognition [44].
Another potential scenario for this underestimation could be that
the arrayed proteins are pre-modified by the conjugation activity
in insect cells prior to spotting on the protein microarrays. This
may at least hold true for ubiquitylation, since there is evidence
that exogenously expressed proteins in Sf9 insect cells can be
ubiquitylated in vivo [45]. However, evidence suggests that even
though they contain SUMOylation machinery, Sf9 cells cannot
support SUMOylation of exogenously expressed human proteins
[46]. Fourthly, being a purely in vitro assay, in vivo regulatory
processes (e.g. temporal or spatial regulations) will likely be lost
during extract preparation. Finally, information regarding the site
of PTM attachment to a substrate cannot be ascertained.
Therefore, our assay system might be most effective when it is
Figure 4. In vivo validation of substrates ubiquitylated on protein microarrays. (A) Ten putative substrates of ubiquitylation identified on
the protein microarrays but not reported in the literature were selected for validation of the modification in vivo. Myc- or GST-substrates were co-
expressed with HA-ubiquitin in HEK293T cells. HEK293T cell extracts were prepared using denaturing conditions, substrates immunoprecipitated with
anti-Myc or anti-GST antibodies, and ubiquitylation detected by immunoblotting with anti-HA antibodies. Empty vector co-expressed with HA-
tagged ubiquitin served as control. Substrates indicated in each lane are: 1- ADRBK2, 2- ACVR1B, 3- PIM2, 4- PRKCgamma, 5- KIF2C, 6- RPS6KA5, 7- ITK,
8- EPHA1, 9- TRIM52, and 10- EPHA5. Of 10 substrates 8 were found to be expressed and immunoprecipitated at detectable levels and of these all
demonstrated evidence of ubiquitylation in vivo. To best visualize an ubiquitin smear, substrates 1, 2, 3, 4 were separated by 10% SDS-PAGE gels,
while larger molecular weight substrates 5, 6, 7, 8 were separated by 6% SDS-PAGE gels. (B) Ubiquitylation of YY1. HEK293T cells were transfected
with plasmids that express HA-ubiquitin, endogenous YY1 protein immunoprecipitated from the denatured extracts, and conjugation to ubiquitin
determined by Western blot analysis with anti-HA antibodies (left). Immunoprecipitation efficiency was determined by probing blots with anti-YY1
antibodies (right). Immunoprecipitation with IgG antibodies of the same species served as control.
doi:10.1371/journal.pone.0011332.g004
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conjugation activities identified should be thoroughly validated in
vivo.
Considering that dysfunction of PTMs play a critical role in a
number of pathological states in humans, this methodology is an
important step forward in the field of proteomics because it will
allow for alterations of PTM activities associated with human
diseases to be identified. For example, SUMOylation is known to
play an important role in maintaining genomic integrity and
preventing tumorigenesis. The SUMOylation machinery is
recruited to sites of DNA damage, and both the tumor suppressor
BRCA1 and the DNA repair factor 53BP1 are substrates of
SUMOylation [47,48,49]. Our methodology could be used to
further unravel the role of SUMOylation in the DNA damage
repair process, such as through comparison profiling of SUMOy-
lation activities from extracts prepared from UV-irradiated and
control cells. A comparison of extracts from normal and cancer
cells with defective DNA damage repair might also help to define
how this process is dysregulated in cancers. Another example are
the deubiquitylating enzymes (DUBs), which function to counter-
act the E3 ubiquitin ligases by removing ubiquitin from substrates
and may play an important role in cancer. One such DUB is A20,
which is an NFkB inhibitor and tumor suppressor [50]. However,
the molecular substrates of A20 are largely unknown. Our
methodology might be employed for these studies by incubating
protein microarrays that were pre-ubiquitylated by cellular
extracts with recombinant A20 protein and profiling for losses in
substrate fluorescence.
In combination with genetic mutants, small molecule pertur-
bants, or RNAi technology, our methodology could help to define
both specific and global aspects of PTMs. Modified cell lines,
disease model systems, and specialized tissues all lend themselves
well to PTM profiling using this approach with the ultimate goal of
furthering our understanding of disease states and identifying
novel therapeutic targets for their treatment.
Materials and Methods
Protein microarrays
Several versions of the ProtoArray Human Protein Microarray
(Invitrogen) were utilized in this study. Profiling experiments
performed with purified ligases, whole-cell extracts, and tumor
extracts utilized version 4 arrays. These protein microarrays
display .8000 purified human proteins (in duplicate) on a
nitrocellulose-coated glass slide. Each of the .8000 human
proteins are derived from human open reading frames (ORF)
that were expressed in Sf9 insect cells as an N-terminal GST fusion
protein.
Extract preparation
Cell lines (HeLa, mouse and human fibroblasts) and tumor
(fresh-frozen human breast cancer tissue) specimens were
suspended in lysis buffer (20 mM Hepes (pH 7.4), 2.5 mM
MgCl2, 0.5 mM DTT, 5 mM NaF, 1 mM sodium orthovana-
date, 1 mM PMSF, 2 mg/ml aprotinin, 1 mg/ml pepstatin, and
1 mg/ml leupeptin) on ice for 15 min and then sonicated briefly.
The extracts were clarified by centrifugation for 15 min at
14,0006 g and snap-frozen in liquid nitrogen until use. Rabbit
reticulocyte lysate and HeLa S-100 fraction were purchased
(Boston Biochem).
Figure 5. In vivo confirmation of SUMO1 and NEDD8 substrates identified on protein microarrays. (A) SUMOylation of IGF-1R.
Endogenous IGF-1R was immunoprecipitated from denatured extracts prepared from HEK293T cells and conjugation to SUMO1 determined by
Western blot analysis with anti-SUMO1 antibodies. Immunoprecipitation efficiency was determined by Western blotting with anti-IGF-1R antibodies
(right). (B) NEDDylation of Musk and Pak3. HEK293T cells were transfected with plasmids that express Flag-Musk or Flag-Pak3 with or without Myc-
NEDD8. Denatured extracts were then immunoprecipitated with anti-Myc or IgG antibodies (control) and conjugation to NEDD8 determined by
Western blotting using anti-Flag antibodies.
doi:10.1371/journal.pone.0011332.g005
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Human SCF
Skp2 complexes were produced in Sf9 insect cells as
described previously [11]. Recombinant Cks1 was produced in
bacteria and purified as described [51]. Cyclin A-Cdk2 complexes
were purchased (Life Technologies).
Antibodies
Antibodies used in this study included: anti-ubiquitin (Biomol,
PW8805); anti-SUMO1 (Zymed, 33-2400); anti-NEDD8 (Zymed,
34-1400); anti-p27
Kip1 (BD pharmingen); anti-c-Src (Biosource);
anti-Skp2 (Zymed), anti-YY1 (Santa Cruz Biotechnology); anti-
IGF-1R (Zymed); anti-HA (Covance); anti-Flag (Sigma); anti-GST
(Santa Cruz Biotechnology); and anti-Myc (9E10, Santa Cruz
Biotechnology).
PTM profiling
Extracts (2-100 mgi n4 0ml of lysis buffer) were combined with
either 4 mM of ubiquitin aldehyde (Boston Biochem) to prevent the
action of deubiquitylating enzymes in the ubiquitylation reactions,
SUMO1 aldehyde to inhibit SUMO-specific isopeptidases
(SENPs) (Boston Biochem) in SUMOylation reactions, or NEDD8
aldehyde to inhibit deNEDDylating and NEDD8 processing
enzymes in NEDDylation reactions (Boston Biochem), and then
incubated at 25uC for 15 min. The reactions were then
supplemented with modifier (1.25 mg/ml), biotin-labeled modifier
(50 ng/ml), Tween-20 (0.1%), energy regenerating system (Boston
Biochem), and 16reaction buffer (ubiquitylation, SUMOylation,
NEDDylation; Boston Biochem) in a final volume of 100 ml.
Proteasome inhibitor MG132 (5 mM) was added to ubiquitylation
reactions. For SCF
Skp2 experiments, reaction conditions were as
described [11]. The reaction mixtures were applied to the protein
microarrays, covered with glass coverslips equipped with rubber
gaskets to avoid leakage (Life Technologies), and then incubated at
37uC for 1 hr in a humidified chamber. The arrays were then
washed in PBS-Tween (0.1%, PBST) containing 1 M NaCl for
10 min, 2610 min in PBST, and then incubated with Streptavidin
Alexa Fluor 647 (100 ng/ml; Life Technologies) for 1 hr at 25uC.
The arrays were then washed 3610 min in PBST and spun dry.
Imaging was performed using a GenePix 4000B Slide Imager
(Molecular Devices) and fluorescent spots analyzed using GenePix
Pro software. Gal files (which contain array production informa-
tion and spot location, identification, and quantification) were
downloaded from www.invitrogen.com and used with GenePix
Pro software to analyze the median intensity of each spot. All data
evaluations were done using the statistical program R [52].
Specifically, we first filtered the data with a cutoff threshold of
5000 counts for the fluorescence values, and then applied the
Benjamini-Hochberg procedure [53] with control of the false
discovery rate (FDR) set at the 5% level. The resulting set of
proteins was used to mine UniProt and PubMed using the
BioConductor modules of R.
Substrate validation experiments
SKP2
2/2 MEFs were transduced with control (pBabe) or 36
FLAG-Skp2 (pBabe-Skp2) retrovirus, and used for validation of
c-Src as a SCF
Skp2 substrate. All in vivo validation experiments
were performed using a technique that preserves the substrate
modification and limits co-purification with non-covalently bound
modifiers of modified interacting proteins [35]. Briefly, HEK293T
cells (ATCC) were lysed under denaturing conditions in 1% SDS
(containing 20 mM N-ethyl-maleimide (NEM)) and boiled briefly
to disrupt non-covalent interactions, and then the buffer adjusted
to 16RIPA (0.1% SDS, 0.5% NP40, 20 mM NEM, 50 mM Tris
(pH 8.5), 150 mM NaCl, 5 mM EDTA, 5 mM NaF, 1 mM
sodium orthovanadate, 1 mM PMSF, 2 mg/ml aprotinin, 1 mg/ml
pepstatin, and 1 mg/ml leupeptin). The expressed or endogenous
putative substrates of ubiquitin, SUMO1, or NEDD8 were then
immunoprecipitated from the extracts as indicated. In all cases,
immunoprecipitation of extracts with IgG antibodies of the same
species served as control.
Supporting Information
Table S1 Proteins whose ubiquitylation status changed with
breast tumor progression. Median values for duplicate proteins
spotted on the array were calculated for on-chip ubiquitylation
reactions differing only by the addition of low or high grade tumor
extract. The proteins are sorted according to a directional measure
of fold-change in ubiquitylation status.
Found at: doi:10.1371/journal.pone.0011332.s001 (0.98 MB
DOC)
Figure S1 Expression level of putative substrates of ubiquityla-
tion that were cloned into Myc- or GST-expression vectors and
used in validation experiments. Ten putative substrates of
ubiquitylation identified on the protein microarrays but not
reported in the literature were selected for validation of the
modification in vivo. These ten substrates were cloned into Myc-
or GST- expression vectors and were co-expressed with HA-
ubiquitin in HEK293T cells. Subsequently, HEK293T cell
extracts were prepared using denaturing conditions. Empty vector
co-expressed with HA-tagged ubiquitin served as control.
Immunoblot, using anti-Myc or anti-GST antibodies, was used
to determine the expression level of each substrate which is
indicated in each lane as: 1- ADRBK2, 2- ACVR1B, 3- PIM2, 4-
PRKCgamma, 5- KIF2C, 6- RPS6KA5, 7- ITK, 8- EPHA1, 9-
TRIM52, and 10- EPHA5.
Found at: doi:10.1371/journal.pone.0011332.s002 (0.03 MB JPG)
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